ScholarLens Back to search
2009•Zhongguo aizheng zazhiRequires access

Advances in palliative chemotherapy for advanced pancreatic cancer

Tianshu Liu

Open publisher page 0 citations

Abstract

With a high invasive ability and poor prognosis, the morbidity of pancreatic cancer is about 98%. Combination of chemotherapy and radiotherapy is the primary management for locoregionally advanced pancreatic cancer, but its effi cacy is limited. Results from a number of meta-analysis have confi rmed that gemcitabine is associated with signifi cantly better clinical response and one-year overall survival rates; therefore, currently gemcitabine is the standard chemotherapy for advanced pancreatic cancer. Gemcitabine-based multi-drug regimens may have potentially favorable effects on patients’ survival. However, evidence from phase Ⅲ clinical trials is lacking. Newer chemotherapy and targeted therapy agents are clearly needed for patients with advanced pancreatic cancer.

About this research paper

What this paper is about

With a high invasive ability and poor prognosis, the morbidity of pancreatic cancer is about 98%. Combination of chemotherapy and radiotherapy is the primary management for locoregionally advanced pancreatic cancer, but its effi cacy is limited. Results from a number of meta-analysis have confi rmed that gemcitabine is associated with signifi cantly better clinical response and one-year overall survival rates; therefore, currently gemcitabine is the standard chemotherapy for advanced pancreatic cancer. Gemcitabine-based multi-drug regimens may have potentially favorable effects on patients’ survival. However, evidence from phase Ⅲ clinical trials is lacking. Newer chemotherapy and targeted therapy agents are clearly needed for patients with advanced pancreatic cancer.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

With a high invasive ability and poor prognosis, the morbidity of pancreatic cancer is about 98%. Combination of chemotherapy and radiotherapy is the primary management for locoregionally advanced pancreatic cancer, but its effi cacy is limited. Results from a number of meta-analysis have confi rmed that gemcitabine is associated with signifi cantly better clinical response and one-year overall survival rates; therefore, currently gemcitabine is the standard chemotherapy for advanced pancreatic cancer. Gemcitabine-based multi-drug regimens may have potentially favorable effects on patients’ survival. However, evidence from phase Ⅲ clinical trials is lacking. Newer chemotherapy and targeted therapy agents are clearly needed for patients with advanced pancreatic cancer.

Key concepts: Gemcitabine, Medicine, Pancreatic cancer, Chemotherapy, Oncology, Internal medicine, Clinical trial, Radiation therapy

Back to paper searchBrowse research topicsOriginal source
Advances in palliative chemotherapy for advanced pancreatic cancer — Research Paper | ScholarLens